LB Pharmaceuticals Inc Common Stock(LBRX)

Biotechnology · New York, NY

$34.17-0.45 (-1.29%)

Delayed quote: Oct 6, 2026, 12:55 PM EDT

LB Pharmaceuticals Inc Common Stock (LBRX) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:21.229Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:57:21.229Z.

Quote observation: 2026-10-06T16:55:05.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 979,981,567
Total debt · period ending 2026-06-30: 5,217,000
Cash · period ending 2026-06-30: 283,111,000
TTM operating EBITDA · period ending 2026-06-30: -94,790,000

FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

LBRX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

LBRX Competitors' EV/EBITDA Ratio

LBRX

LB Pharmaceuticals Inc Common Stock

Current

Market Cap

$979.98M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGTX

MeiraGTx Holdings plc

vs LBRX

Market Cap

$980.52M

EV/EBITDA Ratio

4.83x

TTM Avg

6.06x

3Y Avg

6.06x

5Y Avg

6.06x

PCRX

Pacira BioSciences, Inc.

vs LBRX

Market Cap

$982.98M

EV/EBITDA Ratio

11.48x

TTM Avg

10.94x

3Y Avg

46.55x

5Y Avg

35.86x

AKTS

Aktis Oncology, Inc.

vs LBRX

Market Cap

$976.32M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRCT

PROCEPT BioRobotics Corporation

vs LBRX

Market Cap

$991.81M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LTGO

Latigo Biotherapeutics Inc.

vs LBRX

Market Cap

$1.00B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SVRA

Savara Inc.

vs LBRX

Market Cap

$952.91M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KURA

Kura Oncology, Inc.

vs LBRX

Market Cap

$949.00M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPTX

Seaport Therapeutics, Inc. Common Stock

vs LBRX

Market Cap

$950.17M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLTX

MoonLake Immunotherapeutics

vs LBRX

Market Cap

$938.92M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
LB Pharmaceuticals Inc Common Stock (LBRX)	$979.98M	N/A	N/A	N/A	N/A
MeiraGTx Holdings plc (MGTX)vs ›	$980.52M	4.83x	6.06x	6.06x	6.06x
Pacira BioSciences, Inc. (PCRX)vs ›	$982.98M	11.48x	10.94x	46.55x	35.86x
Aktis Oncology, Inc. (AKTS)vs ›	$976.32M	N/A	N/A	N/A	N/A
PROCEPT BioRobotics Corporation (PRCT)vs ›	$991.81M	N/A	N/A	N/A	N/A
Latigo Biotherapeutics Inc. (LTGO)vs ›	$1.00B	N/A	N/A	N/A	N/A
Savara Inc. (SVRA)vs ›	$952.91M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$949.00M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$950.17M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$938.92M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics